This site is intended for healthcare professionals
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 2
  • /
  • Sandoz launches Hyrimoz biosimilar in Canada.

Sandoz launches Hyrimoz biosimilar in Canada.

Read time: 1 mins
Published:17th Feb 2021
Sandoz Canada Inc. announced the launch of Hyrimoz (adalimumab injection, reference biologic drug: Humira), which was authorized for sale in Canada by Health Canada on November 4, 2020 as one of the four Sandoz biosimilars to be authorized in Canada in the last 11 months. Hyrimoz is indicated for the treatment of nine (9) of the twelve life-threatening or serious debilitating conditions in adults and children covered by the reference medicine, including the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, psoriasis and adult uveitis.
Condition: RA/JIA/AxS/PsA/Ps/HdSup/UvE
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.